VIA EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, NE Washington, D.C. 20549
July 22, 2022
Re:
Facible BioDiagnostics, Inc.
Amendment No. 1 to Offering Statement on Form 1-A
File No. 024-11878
To Whom It May Concern:
On behalf of Facible BioDiagnostics, Inc. (the “Company”), I hereby request qualification of the above-referenced amended offering statement at 5:40PM, Eastern Time, on Wednesday, July 27, 2022, or as soon thereafter as is practicable.
Sincerely,
/s/ Dr. Steven Burden, Ph.D.
Dr. Steven Burden, Ph.D.
Director, Chief Executive Officer, President
Facible BioDiagnostics, Inc.